Prosecution Insights
Prosecution Insights
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STOICA, ELLY GERALD | 1 | 66.7% | +22.8% |
| D' AMBROSIO, THEA | 1 | 55.9% | +56.4% |
| LOUNTOS, GEORGE THEMISTOCLIS | 1 | 33.3% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18003123 | FUSION PROTEIN COMPRISING ANTI-LAG-3 ANTIBODY AND IL-2, AND USE THEREOF | D' AMBROSIO, THEA | 53d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18003123 | FUSION PROTEIN COMPRISING ANTI-LAG-3 ANTIBODY AND IL-2, AND USE THEREOF | D' AMBROSIO, THEA | 53d overdue |
| 18499840 | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT COMPRISING FUSION PROTEIN INCLUDING IL-2 PROTEIN AND CD80 PROTEIN AND ANTICANCER DRUG | STOICA, ELLY GERALD | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| 1654 | 1 |
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18499840 | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT COMPRISING FUSION PROTEIN INCLUDING IL-2 PROTEIN AND CD80 PROTEIN AND ANTICANCER DRUG | STOICA, ELLY GERALD | 1647 | §112DP | Non-Final OA | — | Pending | Nov 01, 2023 |
| 18003123 | FUSION PROTEIN COMPRISING ANTI-LAG-3 ANTIBODY AND IL-2, AND USE THEREOF | D' AMBROSIO, THEA | 1654 | §102§103§112 | Final Rejection | 53d overdue | Pending | Dec 22, 2022 |
| 17912403 | FUSION PROTEIN COMPRISING IL-2 PROTEIN AND CD80 PROTEIN FRAGMENT OR VARIANT THEREOF, AND USES THEREOF | LOUNTOS, GEORGE THEMISTOCLIS | 1652 | §102§103§112DP | Final Rejection | — | Pending | Sep 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial